Scarica l'app Stockscreener
15.70
4.98%
-0.77
Precedente Chiudi:
$16.47
Aprire:
$16.65
Volume 24 ore:
115.54K
Relative Volume:
0.56
Capitalizzazione di mercato:
$749.77M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-10.48
EPS:
-1.4981
Flusso di cassa netto:
-
1 W Prestazione:
-16.35%
1M Prestazione:
-4.75%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$15.60
$16.82
Intervallo di 1 settimana:
$15.60
$18.95
Portata 52W:
$15.60
$20.00
Odyssey Therapeutics Inc Stock (ODTX) Company Profile
Nome
Odyssey Therapeutics Inc
Settore
Industria
Telefono
(212) 841-1000
Indirizzo
51 SLEEPER STREET, BOSTON
Compare ODTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ODTX
Odyssey Therapeutics Inc
|
15.61 | 791.08M | 0 | 0 | 0 | -1.4981 |
VRTX
Vertex Pharmaceuticals Inc
|
522.00 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.13 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.99 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Odyssey Therapeutics Inc Borsa (ODTX) Ultime notizie
Odyssey Therapeutics (ODTX) Earnings Date and Reports 2026 - MarketBeat
Odyssey Therapeutics prices upsized IPO at $18 per share - Investing.com
Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower - Stocktwits
Odyssey Therapeutics Inc (ODTX) Dividend News Alerts - DividendInvestor.com
ODTX Price Today: Odyssey Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
Enterprise value to EBIT forward of Odyssey Therapeutics, Inc. – NASDAQ:ODTX - TradingView
Odyssey Therapeutics (ODTX) Stock Trends and Sentiment 2026 - MarketBeat
Form 8K ODYSSEY THERAPEUTICS For: 23 June By Investing.com - Investing.com Nigeria
Odyssey posts June 2026 corporate presentation highlighting OD-001 Phase 2a results and $464M pro forma cash - TradingView
Odyssey Therapeutics (NASDAQ: ODTX) details I&I pipeline, OD-001 data and cash - Stock Titan
Odyssey Therapeutics, Inc.(NasdaqCM: ODTX) added to S&P TMI Index - marketscreener.com
Odyssey Therapeutics, Inc. (ODTX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT) - The Globe and Mail
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
TD Cowen Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating - Moomoo
ODTX Reiterated by Oppenheimer -- Price Target Maintained at $40 - GuruFocus
Oppenheimer Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Odyssey Therapeutics: Q1 Earnings Snapshot - AOL.com
Odyssey Therapeutics, Inc. 2026 Q1 10-Q Report: Clinical Progress, Risk Factors, and Financial Overview - Minichart
Odyssey Therapeutics Q1 EPS $(6.77) misses $(1.13) estimate - scanx.trade
Odyssey Therapeutics reports Q1 2026: $38.3M net loss, $464.4M pro forma cash to fund into H2 2028 - TradingView
Odyssey Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(6.77) — 10-Q Summary - TradingView
ODTX: Strong clinical progress and IPO proceeds position the company for late-stage development - TradingView
ODTX SEC FilingsODYSSEY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Odyssey Therapeutics (Nasdaq: ODTX) posts Q1 loss but secures $464M cash - Stock Titan
Odyssey Therapeutics reports positive OD-001 data and $464.4M cash position - scanx.trade
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Odyssey Therapeutics Reports Positive Phase 2a Proof-of-Concept Data for OD-001 in Ulcerative Colitis and Q1 2026 Financial Results - Quiver Quantitative
Odyssey Therapeutics sees ulcerative colitis signal in Phase 2a trial - Stock Titan
Odyssey Therapeutics Ord Shs (Proposed) (ODTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wedbush Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
FMR LLC's Strategic Acquisition of Odyssey Therapeutics Inc Shar - GuruFocus
Anthony W. Opipari Net Worth (2026) - GuruFocus
Aranicki Ksenija Pavletic Net Worth (2026) - GuruFocus
Todd Collin M Net Worth (2026) - GuruFocus
Natalie Dales Net Worth (2026) - GuruFocus
Gary D Glick Net Worth (2026) - GuruFocus
ODTXOdyssey Therapeutics Inc Stock Price and Quote - Finviz
FMR LLC discloses 4.58M-share stake in Odyssey Therapeutics (ODTX) - Stock Titan
Odyssey Therapeutics (ODTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
ODTX Technical Analysis & ETF Price Forecast - Intellectia AI
Latest ODTX ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
ODTX Initiates Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
ODTX Initiates Coverage by JP Morgan -- Price Target Set at $26 - GuruFocus
ODTX Initiated Coverage by Cantor Fitzgerald -- Rated Overweight - GuruFocus
ODTX Initiates Coverage by Wedbush -- Price Target Announced at $30 - GuruFocus
Odyssey Therapeutics (ODTX) Rated Outperform with $30 Target - GuruFocus
ODTX Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Odyssey Therapeutics Inc Azioni (ODTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Odyssey Therapeutics Inc Azioni (ODTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dimension Capital II, L.P. | Director |
May 08 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
1,831,383 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 11 '26 |
Sale |
18.00 |
1,780 |
32,040 |
440,981 |
| LEIDEN JEFFREY M | Director |
May 08 '26 |
Buy |
20.00 |
5,000 |
100,000 |
270,198 |
| Haas Jason | Chief Financial Officer |
May 08 '26 |
Buy |
20.00 |
1,000 |
20,000 |
62,908 |
| Li Nan (LN) | Director |
May 11 '26 |
Buy |
18.00 |
1,111,111 |
19,999,998 |
3,333,516 |
| Chu Shelley | Director |
May 11 '26 |
Buy |
18.00 |
11,111 |
199,998 |
11,111 |
1.21%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):